Cultured meat for pets

01Overview and value chain

Markers: [EC: FDA ’no questions’ pre-market notification pathway | OECD: Food systems | Regulator: FDA (USA)]

Cultured meat for pets covers two distinct production routes reaching the same shelf: precision-fermented animal proteins (yeast expressing a specific meat protein, no animal cells involved) and true cell-cultured meat (animal cells grown and harvested as tissue). The UK became the first European country to approve cultivated meat for any market — in pet food, not human food — when Meatly received regulatory clearance to sell cultivated chicken in July 2024. In the US, Bond Pet Foods obtained an FDA ’no questions' letter for a yeast-brewed lamb protein co-developed with Hill’s Pet Nutrition, a top-five global pet food brand, while BioCraft Pet Nutrition reports reaching price parity between its cultivated mouse meat and premium pet food after re-engineering its growth-media chemistry. Pet food is emerging as the more permissive first market for cultured proteins largely because regulators and consumers alike tolerate ingredients (mouse, hamster) that would be commercially unworkable for human consumption.

Key directions of cultured meat for pets:

1. Precision-fermented pet proteins (Precision-Fermented Pet Proteins): yeast or microbial hosts engineered to express a single named meat protein (e.g., lamb, chicken) with no animal cells in the final product.
2. Cell-cultured novel-species meat (Cell-Cultured Novel-Species Meat): true cultivated meat grown from mouse or hamster cell lines, avoiding the food-safety and scale hurdles of cultivating cow/chicken cells at pet-food price points.
3. Major pet-brand co-development (Major Pet-Brand Co-Development): an established pet food company partners directly with a cultured-protein startup to bring the ingredient to market under its own brand.
4. First-market regulatory entry via pet food (First-Market Regulatory Entry via Pet Food): securing an initial approval in pet food, where the regulatory and consumer-acceptance bar is lower than human food, ahead of any human-food filing.

Sectoral value chain

[cell line/strain selection] ──> [growth-media engineering] ──> [bioreactor scale-up] ──> [harvest/formulation]
                                                                        │
                                                                (regulatory
                                                                 clearance)
                                                                        │
                                                                        ▼
[pet food shelf] <─── [brand co-development] <────────────────────────┘

Value chain levels

Cross-cutting technologies of the sector:

• Serum-free growth-media formulation (Serum-Free Growth-Media Formulation): replacing costly fetal bovine serum with defined, lower-cost media to reach pet-food price points.
• Precision fermentation expression hosts (Precision Fermentation Expression Hosts): yeast strains engineered to secrete a single target meat protein at scale.
• Novel-species cell culture (Novel-Species Cell Culture): cultivating mouse/hamster cell lines specifically because they face a lower regulatory and cost bar than cow/chicken cells.

02US

The US combines an FDA precedent for a precision-fermented pet protein with a direct partnership between a cultured-protein startup and a top pet food brand.

FDA no-questions letters, major-brand co-development, precision-fermented proteins

• Bond Pet Foods: received an FDA ’no questions’ letter for a yeast-brewed lamb protein co-developed with Hill’s Pet Nutrition, and took an investment from flavor and ingredients group Symrise to expand precision-fermented pet nutrition products.
• Major-brand validation: Hill’s Pet Nutrition’s direct five-year co-development relationship with Bond is one of the clearest signals of incumbent pet food industry buy-in for cultured/fermented proteins.

03CN

Public information on a dedicated Chinese cultured-meat-for-pets originator was not confirmed in this pass; China’s pet food market is large and growing, but the section stays at the policy level.

pet food market growth, no confirmed domestic cultured-protein originator, import/licensing pathway

• Large and growing pet food market: China’s pet food sector is one of the fastest-growing globally, creating latent demand for novel-protein ingredients.
• No confirmed domestic originator: a Chinese company developing cultured or precision-fermented meat specifically for pet food was not confirmed via live sources in this pass.
• Likely entry via licensing: as in several other novel-protein categories, US/EU-originated cultured pet-protein ingredients are more likely to reach China initially via licensing or import than domestic origination.

04EU

The EU is the most active cultured-meat-for-pets region by regulatory firsts, spanning UK approval, an Austrian cell-cultured originator and a Czech novel-species meat producer.

UK first-in-Europe approval, Austrian/Czech cell-culture originators, feeding-trial evidence

• Meatly: the first cultivated-meat company approved for sale in any European country, cleared by UK regulators in July 2024 to sell cultivated chicken in pet food.
• BioCraft Pet Nutrition: an Austria-based originator of cell-cultured mouse meat that reports reaching price parity with premium pet food and has partnered with Prefera Petfood to launch a cultivated-mouse cat food.
• BeneMeat: a Czech cultivated-hamster-meat producer whose feeding trials found cats readily accept and digest the cultivated product, leaving fewer scraps than with conventional chicken.

05Leading companies and research institutes

06Tech stack and innovations

The stack pairs cost-driven media engineering with a choice of species that lowers the regulatory bar.

1. Novel-species cell selection (Novel-Species Cell Selection):
   • mouse and hamster cell lines are chosen specifically because cultivating them faces a lower regulatory and technical bar than cow or chicken cells at pet-food price points.
   • case: BeneMeat’s cultivated hamster meat was accepted and digested by cats as well as, or better than, conventional chicken in a feeding trial.
2. Growth-media cost re-engineering (Growth-Media Cost Re-Engineering):
   • reformulating the growth medium away from costly serum-based formulations is the single biggest lever on unit cost.
   • case: BioCraft reports its cultivated mouse meat reaching price parity with premium pet food after re-engineering its media chemistry.
3. Yeast-brewed single-protein expression (Yeast-Brewed Single-Protein Expression):
   • a yeast host is engineered to secrete one named meat protein without any animal cells in the final ingredient.
   • case: Bond Pet Foods’ yeast-brewed lamb protein cleared FDA review specifically as a fermentation product, not a cultivated-cell product.

07Value chains and production pipelines

Industrial pipeline of a cultured pet-protein ingredient (FDA pre-market notification)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Strain/line selection  │ ───> │ 2. Media engineering      │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Regulatory dossier     │ <─── │ 3. Bioreactor scale-up    │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Brand co-development   │ ───> │ 6. Shelf launch & feeding trial│
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Strain/line selection

A yeast expression host or a mouse/hamster cell line is selected based on regulatory precedent and production cost.

Stage 2: Media engineering

The growth medium is reformulated away from costly serum-based inputs to reach a pet-food-viable unit cost.

Stage 3: Bioreactor scale-up

Fermentation or cell culture is scaled in bioreactors to produce protein or biomass at commercial volume.

Stage 4: Regulatory dossier

A safety dossier is filed for FDA no-questions review (US) or the equivalent national process (UK).

Stage 5: Brand co-development

An established pet food brand (e.g., Hill’s Pet Nutrition, Prefera Petfood) formulates the cleared ingredient into a finished product.

Stage 6: Shelf launch & feeding trial

The product launches with feeding-trial data on acceptance and digestibility tracked against a conventional-meat baseline.